Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Short-term Investments: 2015-2017

Historic Short-term Investments for Adma Biologics (ADMA) over the last 3 years, with Dec 2017 value amounting to $1.5 million.

  • Adma Biologics' Short-term Investments fell 72.17% to $1.5 million in Q4 2017 from the same period last year, while for Dec 2017 it was $1.5 million, marking a year-over-year decrease of 72.17%. This contributed to the annual value of $1.5 million for FY2017, which is 72.17% down from last year.
  • According to the latest figures from FY2017, Adma Biologics' Short-term Investments is $1.5 million, which was down 72.17% from $5.4 million recorded in FY2016.
  • Adma Biologics' 5-year Short-term Investments high stood at $6.4 million for FY2015, and its period low was $1.5 million during FY2017.
  • Over the past 3 years, Adma Biologics' median Short-term Investments value was $5.4 million (recorded in 2016), while the average stood at $4.4 million.
  • Data for Adma Biologics' Short-term Investments shows a maximum YoY slumped of 72.17% (in 2017) over the last 5 years.
  • Yearly analysis of 3 years shows Adma Biologics' Short-term Investments stood at $6.4 million in 2015, then declined by 15.36% to $5.4 million in 2016, then plummeted by 72.17% to $1.5 million in 2017.